MTX-101 (Mozart Therapeutics)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameMTX-101 (Mozart Therapeutics)
Drug Alias NameMTX-101 (Mozart Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 8 modulatorsKIR receptors modulators
TargetsCluster of differentiation 8KIR receptors
Therapy Area/IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMozart Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMozart Therapeutics IncMozart Therapeutics Australia Pty Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A